Vivaldi Coelho Rogerio — SEC insider filings
SEC reporting owner CIK 1610381. 23 insider filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2020-12-10 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $110,300 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 8,000 shares, $300,761 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 41.
- Largest priced transaction: sale of 4,477 shares @ $36.08 ($161,530) in Crinetics Pharmaceuticals, Inc., filed 2026-03-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | Director | 11 | 1 leg · 5,000 sh · $110,300 | 3 legs · 8,000 sh · $300,761 | 19 |
| Sigilon Therapeutics, Inc. (SGTX) | PRESIDENT AND CEO, Director | 8 | — | — | 11 |
| Viatris Inc (VTRS) | Director | 4 | — | — | 11 |
Insider filings — Vivaldi Coelho Rogerio
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to issuer (D): 13,300 @ $85 · Disposition to issuer (D): 5,925 @ $85 · Disposition to issuer (D): 35,000 (derivative) @ $56.69 · Disposition to issuer (D): 8,750 (derivative) @ $66.71 · Disposition to issuer (D): 17,500 (derivative) @ $64.68 · Disposition to issuer (D): 12,500 (derivative) @ $40.29 · +2 more | EDGAR |
| 2026-07-07 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 3,000 @ $40 | EDGAR |
| 2026-06-22 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 4,477 @ $36.08 · Sale (S): 523 @ $36.77 | EDGAR |
| 2026-03-10 | 4 | Viatris Inc (VTRS) | Option exercise (M): 23,660 @ $0 · Option exercise (M): 1,175 @ $0 · Option exercise (M): 23,660 (derivative) @ $0 · Option exercise (M): 1,174.49 (derivative) @ $0 · Grant/award (A): 15,890 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Viatris Inc (VTRS) | Grant/award (A): 23,660 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Viatris Inc (VTRS) | Option exercise (M): 21,267 @ $0 · Option exercise (M): 424 @ $0 · Option exercise (M): 21,267 (derivative) @ $0 · Option exercise (M): 423.01 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 3,400 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Viatris Inc (VTRS) | Grant/award (A): 21,267 (derivative) @ $0 | EDGAR |
| 2023-08-11 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Disposition to issuer (D): 12,169 · Disposition to issuer (D): 35,382 (derivative) @ $0.75 | EDGAR |
| 2023-07-24 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Option exercise (M): 5,528 @ $19.24 · Option exercise (M): 5,528 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 6,000 @ $0 · Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Purchase (P): 5,000 @ $22.06 | EDGAR |
| 2023-03-01 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 460,000 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 8,750 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4/A | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-02-22 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 230,000 (derivative) @ $1.48 | EDGAR |
| 2022-01-10 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 400,000 (derivative) @ $3.03 | EDGAR |
| 2021-11-05 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2021-02-16 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2020-12-10 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Conversion (C): 22,222 · Conversion (C): 22,222 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1610381 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs